CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise | +2,000 | 41,242 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise | +3,750 | 44,992 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise | +2,858 | 47,850 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Sale | −3,841 | $12.01 | $46K | 44,009 |
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −1,924 | 3,849 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −2,000 | 6,000 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −3,750 | 26,250 | ||
| 2025-07-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −2,858 | 31,442 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,207 | 64,723 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,000 | 66,723 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,750 | 70,473 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,858 | 73,331 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Sale | −4,308 | $12.01 | $52K | 69,023 |
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 6,414 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 6,000 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,750 | 26,250 | ||
| 2025-07-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,858 | 31,442 | ||
| 2025-05-19 | Silva Paul M Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-05-19 | Kunkel Lori Anne Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2025-05-19 | GREGORY JULIA P Director | Grant or award · Director Stock Option (right to buy) | +25,000 | 25,000 |
Page 12 of 20 · 381 trades